PLK1 and central nervous system cancer: Mice bearing intracranial U87 gliomas, when given iRGD‐modified PLK1‐2‐targeted LHNPs, showed an improved survival rate along with a decrease in PLK1 expression up to 60.4%.[66] In another study, the CRISPR/Cas9 plasmid was delivered using a natural polymer functionalized with aptamer (AS1411)‐conjugated hyaluronic acid and TAT–NLS‐peptide‐conjugated hyaluronic acid.